Search

Lilly, Vir Biotechnology and GSK announce positive topline data from the phase 2 BLAZE-4 trial evaluating bamlanivimab with VIR-7831 in low-risk adults with COVID-19

Media

In combination, the 2 monoclonal antibodies demonstrated 70% relative reduction in persistent high viral load at day 7 compared to placebo.

https://www.gsk.com/en-gb/media/press-releases/lilly-vir-biotechnology-and-gsk-announce-positive-topline-data-from-the-phase-2-blaze-4-trial-evaluating-bamlanivimab-with-vir-7831-in-low-risk-adults-with-covid-19/

First published: 29 March 2021

GSK and Vir Biotechnology announce continuing progress of the COMET clinical development programme for sotrovimab

Media

U.S. National Institutes of Health (NIH) COVID-19 Treatment Guidelines updated to recommend use of sotrovimab.

https://www.gsk.com/en-gb/media/press-releases/gsk-and-vir-biotechnology-announce-continuing-progress-of-the-comet-clinical-development-programme-for-sotrovimab/

First published: 21 June 2021

GSK and Vir Biotechnology announce United States government agreements to purchase sotrovimab, a COVID-19 treatment

Media

US government contracts for approximately $1 billion (USD) now in place to purchase sotrovimab, further expanding access nationwide

https://www.gsk.com/en-gb/media/press-releases/gsk-and-vir-biotechnology-announce-united-states-government-agreements-to-purchase-sotrovimab-a-covid-19-treatment/

First published: 17 November 2021

Vir Biotechnology and GSK announce start of NIH-sponsored ACTIV-3 trial evaluating VIR-7831 in hospitalised adults with COVID-19

Media

Global Phase 3 trial will investigate the safety and efficacy of VIR-7831 in hospitalised adults with COVID-19

https://www.gsk.com/en-gb/media/press-releases/vir-biotechnology-and-gsk-announce-start-of-nih-sponsored-activ-3-trial-evaluating-vir-7831-in-hospitalised-adults-with-covid-19/

First published: 17 December 2020

New Zealand

Locations

GSK New Zealand

https://www.gsk.com/en-gb/locations/new-zealand/

First published: 09 May 2025